Aug 08, 2013
This is the fourth drug discovery project funded by Families of SMA in 2013 with a total investment of $550,000.
May 06, 2013
This funding is being awarded to Co-Principal Investigators Dr. Arthur Burghes at Ohio State University and Dr. Christian Lorson at University of Missouri.
Apr 30, 2013
15 new drugs now in development for SMA. 3 in active clinical trials. 11 companies investing in SMA drug programs.
Mar 20, 2013
This funding will build on the consensus statement for the standard of care for SMA with data driven results on specific areas of SMA care such as respiratory, nutritional, and surgical interventions.
Mar 18, 2013
This three-year multi-million dollar cooperative agreement to Brian Kaspar, PhD, principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital in the amount of $3,752,462, funds pre-clinical drug...
Jan 18, 2013
Dr. Rubin's project at Harvard is the first of three drug discovery awards that will be given by Families of SMA in the next few months.
Jan 04, 2013
Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).
Dec 30, 2012
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program.
Dec 27, 2012
Continued investment in basic research leads to greater understanding of the exact nature, causes, and consequences of SMA.
Dec 26, 2012
This new research funding will support a project at Northwestern University to better understand when and where SMN protein is needed in less severe SMA.